Gilead Sciences Inc
GILD XNAS
$151.37
+0.00 (+0.00%)
▲
15-min delayed
Open
N/A
High
N/A
Low
N/A
Volume
N/A
Market Cap
$187.69B
About Gilead Sciences Inc
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Key Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $7.80B | $-10,496,000,000 | $-8.45 |
| Q1 2026 | $6.96B | $2.02B | $1.63 |
| FY 2025 | $29.44B | $8.51B | $6.84 |
| Q3 2025 | $7.77B | $3.05B | $2.46 |
TickerDaily Coverage
Healthcare Stocks This Week: XLV Gains 2.1% as UNH, LLY Lead Sector Rally (Aug 3–7, 2026)
Market News
David Brooks · Aug 7, 2026
The healthcare sector finished the week with solid momentum, as the Health Care Select Sector SPDR...
Stock Market This Week: Earnings Preview for August 3-7, 2026 — Disney, Eli Lilly, Caterpillar Lead Earnings Deluge
Market News
David Brooks · Jul 27, 2026
The stock market enters earnings season's heaviest week with mega-cap reports from Disney, Eli...
Healthcare Stocks This Week: XLV Outperforms on Rate Cut Bets — Weekly Roundup (Jun 29 – Jul 3, 2026)
Market News
David Brooks · Jul 3, 2026
The healthcare sector capped a record-breaking first half with a strong week as XLV rallied on...
Healthcare Stocks This Week: XLV Outperforms Amid Pharma Strength (Jun 15–19, 2026)
Market News
David Brooks · Jun 19, 2026
The healthcare sector finished the week with measurable gains as large-cap pharma stocks and...
Healthcare Stocks This Week: XLV Underperforms Tech Rally Amid Inflation Concerns (Jun 1–5, 2026)
Market News
David Brooks · Jun 5, 2026
The healthcare sector underperformed the broader market during the week of June 1–5, 2026, with the...
View All Coverage →
Get GILD Alerts
Stay ahead with breaking news, price alerts, and expert analysis on Gilead Sciences Inc.
Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.